Modelos de datos seleccionados

Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.

5 Resultados de la búsqueda.
Relevancia Evaluación Nuevo primero Antiguo primero

Basic documentation B2 LeMLAR-Studie Lymphoma NCT01788189 - Basic documentation B2

- 15/3/21 - 1 formulario, 3 itemgroups, 26 items, 1 idioma
Itemgroups: medical history, Inclusion Criteria, Exclusion Criteria
Study part: Basic documentation B2 LeMLAR-Studie. LeMLAR-Studie. Lenalidomide in conjunction with methotrexate, leucovorin, cytarabine and rituximab for the treatment of relapsed or refractory CD20-positive aggressive lymphomas: an open-label, multicenter phase I/II trial. Publication granted by Prof. Dührsen and provided by Claudia Ose, University clinic Essen, NCT01788189, Version 1.3-28.04.2013.doc.

GSK Study ID 100807 Fluticasone Propionate from SERETIDE™ (500/50) DISKUS™ and Budesonide from Symbicort (200/6) Turbuhaler in patients with severe Chronic Obstructive Pulmonary Disease. Subject Diary Card - Subject Diary Card

- 10/10/17 - 1 formulario, 3 itemgroups, 48 items, 1 idioma
Itemgroups: Subject Diary Card, Subject Diary Card, Subject Diary Card Treatment Period 2
Randomised, open label, two period, crossover study to compare the steroid systemic exposure of Fluticasone Propionate (FP) from FP/Salmeterol (SALM) (500/50) DISKUS and Budesonide (BUD) from BUD/formoterol (FOR).(200/6) Turbuhaler in patients with severe Chronic Obstructive Pulmonary Disease. Primary objective:To compare the exposure of the inhaled steroid fluticasone propionate (FP) and budesonide following repeat dosing with SERETIDE DISKUS (500/50) one inhalation twice daily (b.i.d.) when compared with Symbicort Turbuhaler (200/6) two inhalations b.i.d. in a severe chronic pulmonary obstructive disease (COPD) population. Secondary objectives:To compare the pharmacokinetics of FP and budesonide following repeat dosing with SERETIDE DISKUS (500/50) one inhalation b.i.d. when compared with Symbicort Turbuhaler (200/6) two inhalations b.i.d. in a severe COPD population and to explore further the pharmacokinetics of FP and budesonide.

daily record card administration salmeterol/fluticasone propionate combination compared to salmeterol on COPD 100470

- 16/8/17 - 1 formulario, 2 itemgroups, 7 items, 1 idioma
Itemgroups: administrative data, next clinic visit
Study ID: 100470 Clinical Study ID: SCO100470 Study Title: A multicentre, randomised, double-blind, parallel group, 24 week study to compare the effect of salmeterol/fluticasone propionate combination product 50/250mcg, with salmeterol 50mcg both delivered twice daily via DISKUS®/ACCUHALER® inhaler on lung function and dyspnoea in subjects with Chronic Obstructive Pulmonary Disease (COPD). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor:GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone propionate/salmeterol Trade Name: Serevent Study Indication: Pulmonary Disease, Chronic Obstructive

daily record card documentation salmeterol/fluticasone propionate combination compared to salmeterol on COPD 100470

- 16/8/17 - 1 formulario, 4 itemgroups, 19 items, 1 idioma
Itemgroups: administrative data, documentation of health status, symptoms of COPD, worksheet
Study ID: 100470 Clinical Study ID: SCO100470 Study Title: A multicentre, randomised, double-blind, parallel group, 24 week study to compare the effect of salmeterol/fluticasone propionate combination product 50/250mcg, with salmeterol 50mcg both delivered twice daily via DISKUS®/ACCUHALER® inhaler on lung function and dyspnoea in subjects with Chronic Obstructive Pulmonary Disease (COPD). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor:GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone propionate/salmeterol Trade Name: Serevent Study Indication: Pulmonary Disease, Chronic Obstructive

Baseline RICH study NCT02669589

- 12/6/16 - 1 formulario, 21 itemgroups, 234 items, 1 idioma
Itemgroups: Patient Information, Patient Data, Kidney Disease: Improving Global Outcomes (KDIGO), Renal function, Neurologic dysfunction, Pulmonary dysfunction, Cardiovascular disorder, Gastrointestinal dysfunction, Other organ dysfunction, Main diagnosis for admission, Pre-existing illness, Premedication, Glasgow Coma Scale, Mechanical ventilation, Catecholamine and inotropic therapy, Vital signs, Concomitant medication, Laboratory Parameters and Blood Gas Analysis, Fluid balance, Transfusion, Microbiology
NCT02669589 EudraCT-Nr. 2014-004854 [Titel anhand dieser ISBN in Citavi-Projekt übernehmen] -33 REGIONAL CITRATE VERSUS SYSTEMIC HEPARIN ANTICOAGULATION FOR CONTINUOUS RENAL REPLACEMENT THERAPY IN CRITICALLY ILL PATIENTS WITH ACUTE KIDNEY INJURY Study Chair: Alexander Zarbock, MD University Hospital Muenster

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial